The Inflammatory Bowel Disease Treatment Market Insights And Analysis by Drug Class (TNF Inhibitors, Aminosalicylates) Disease Indication (Ulcerative Colitis, Crohn’s Disease) Distribution Channel (Hospital Pharmacy), End-User (Hospitals & Clinics)—Forecast till 2030
During the forecast period, the Inflammatory Bowel Disease Treatment Market is expected to grow at a CAGR of 5%. Over the next few years, the market is likely to increase because ulcerative disease and Crohn's disease are becoming more common around the world. In the coming years, the market is expected to grow because more people are using biologics to treat and because there are strong pipeline drugs like risankizumab, upadacitinib, tofacitinib, ustekinumab, and others. The COVID-19 pandemic didn't have much effect on the market in 2020. However, many countries have seen a drop in the number of people being diagnosed with inflammatory bowel disease because of the complete lockdown.
The market is split into two groups based on the diseases they treat: ulcerative colitis and Crohn's disease.
People with Crohn's disease are expected to make up the largest part of the market. This segment is growing because Crohn's disease is becoming more common and because more people around the world are getting treatment for Crohn's disease.
The injectables market is expected to grow because of factors like the growing use of biologics to treat ulcerative colitis and Crohn's disease and the growth of product approvals for biologics.
The market has been split by drug class into IL inhibitors, JAK inhibitors, TNF inhibitors, anti-integrin, ASA drugs, corticosteroids, and others.
The largest part of the market was made up of TNF inhibitors. Patients of inflammatory bowel disease can use monoclonal antibodies to target remission and keep it going. This is helping the segment grow in the market.
In 2020, North America led the Inflammatory Bowel Disease Treatment Market Trends therapy, with a revenue share of around 60.0%. During the projection period, the area is anticipated to have profitable growth. High treatment rates, a rise in the prescription of innovative pharmaceuticals, and improved reimbursement regulations in the region contribute to market expansion.
In addition, rising research and development initiatives to produce better treatment choices, as well as the presence of large pharmaceutical firms in the area, are likely to drive market expansion throughout the projection period. As stated by the U.S. National Library of Medicine, there are a total of 730 clinical studies connected to IBD as of October 2019, 268 of which are being undertaken only in the United States.
Asia-Pacific is expected to have a higher CAGR because more people are becoming aware of ulcerative colitis and Crohn's disease there. In addition, more and more drugs are being approved to treat these diseases.
March 2022 – Pfizer Inc. acquires Arena Pharmaceuticals, a clinical-stage business developing potential revolutionary treatments for the treatment of a variety of immuno-inflammatory diseases. This breakthrough assisted the firm in diversifying its portfolio for a number of immuno-inflammatory disorders, including ulcerative colitis, Crohn's disease, and others.
Bristol Myers Squibb announced in May 2021 that the Food and Drug Administration had authorized Zeposia (ozanimod) for the treatment of people with moderate to severely active ulcerative colitis.
STELARA was authorized to treat mild to severely active ulcerative colitis in the EU in September 2019.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071